Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Clinical Studies
  • Investors
  • Obligations convertibles
    • Documents liés à l'émission et à la conversion d'obligations convertibles
    • Nouveau dénominateur en date du 28 avril 2026
    • Nouveau dénominateur en date du 08 mai 2025
  • News
  • En
  • Français

English version is not updated since 2025-01-01.

BioSenic

New SOLUTIONS

for inflammatory diseases and bone disorders

Our Team
Products
Investors
BioSenic

New SOLUTIONS

for inflammatory diseases and bone disorders

Our Team
Products
Investors
BioSenic

New SOLUTIONS

for inflammatory diseases and bone disorders

Our Team
Products
Investors

Our Executive Team

Products

BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for inflammatory diseases and bone disorders, as well as medical devices for these same areas.

Investors

All regulatory information and reports.

 

Études cliniques

Learn more about clinical development and our ongoing studies.

 

BioSenic publie ses résultats pour le premier semestre 2026

Communiqué de presse: H1 2026 - Biosenic.

Notre technologie

BioSenic aims to become a leading company in the field of regenerative and immune medicine by developing innovative products for inflammatory diseases and bone disorders.

 

Prix de l’action

BioSenic ( BIOS )

0.002€

26.05.2026

Wallonie Eu Flag

BioSenic SA
Avenue Léon champagne, 3
1480 Saintes – Belgium
info@biosenic.com
 

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions